Clinician's Pocket Drug Reference 2008

82 Dipivefrinbleeding disorders. Disp: Single-dose vials 0.5 mL SE: Drowsiness, restlessness,fever, fussiness, ↓ appetite, nodule redness, inj site pain/swelling Notes: If IM useonly preservative-free injectionDipivefrin (Propine) Uses: *Open-angle glaucoma* Action: α-Adrenergicagonist Dose: 1 gtt in eye q12h Caution: [B, ?] Contra: NAG Disp: 0.1% solnSE: HA, local irritation, blurred vision, photophobia, HTNDipyridamole (Persantine) Uses: *Prevent postop thromboembolic disorders,often in combo w/ ASA or warfarin (eg, CABG, vascular graft); w/ warfarinafter artificial heart valve; chronic angina; w/ ASA to prevent coronary arterythrombosis; dipyridamole IV used in place of exercise stress test for CAD* Action:Anti-plt activity; coronary vasodilator Dose: Adults. 75–100 mg PO tid–qid;stress test 0.14 mg/kg/min (max 60 mg over 4 min). Peds >12 y. 3–6 mg/kg/d dividedtid (safety/efficacy not established) Caution: [B, ?/–] w/ other drugs that affectcoagulation Contra: Component sensitivity Disp: Tabs 25, 50, 75 mg; inj5 mg/mL SE: HA, ↓ BP, N, abd distress, flushing rash, dizziness, dyspnea Notes:IV use can worsen anginaDipyridamole & Aspirin (Aggrenox) Uses: *↓ Reinfarction afterMI; prevent occlusion after CABG; ↓ risk of stroke* Action: ↓ Plt aggregation(both agents) Dose: 1 cap PO bid Caution: [C, ?] Contra: Ulcers, bleeding diathesisDisp: Dipyridamole (XR) 200 mg/aspirin 25 mg SE: ASA component: allergicRxns, skin Rxns, ulcers/GI bleed, bronchospasm; dipyridamole component: dizziness,HA, rash Notes: Swallow capsule wholeDirithromycin (Dynabac) Uses: *Bronchitis, community-acquired pneumonia,& skin & skin structure Infxns* Action: Macrolide antibiotic. Spectrum:M. catarrhalis, Streptococcus pneumoniae, Legionella, H. influenzae, S. pyogenes,S. aureus Dose: 500 mg/d PO; w/ food; swallow whole Caution: [C, M] Contra:w/ pimozide Disp: Tabs 250 mg SE: Abd discomfort, HA, rash, ↑ K +Disopyramide (Norpace, Norpace CR, NAPamide, Rhythmodan)WARNING: Excessive mortality or nonfatal cardiac arrest rate withuse in asymptomatic non-life-threatening ventricular arrhythmias with MI 6 daysto 2 years prior. Restrict use to life-threatening arrhythmias only Uses: *Suppression& prevention of VT* Action: Class 1A antiarrhythmic; stabilizes membranes,depresses action potential Dose: Adults. 400–600 mg/d ÷ q6h or q12h for CR,max 1600 mg/day. Peds. 5 mcg/mL; 1 ⁄2 life:4–10 hDobutamine (Dobutrex) Uses: *Short-term in cardiac decompensationsecondary to depressed contractility* Action: Positive inotrope Dose: Adults &